‹ Back to the alert

Prints on one A4 page for most notices. Long batch lists carry on to a second page, with the column headings repeated.

Defect notification check

Class 4 Medicines Defect Notification: Star Pharmaceuticals Ltd, Enalapril maleate/ Hydrochlorothiazide 20 mg/12.5 mg Tablets, EL(26)A/48

Class 4 defect notification — Caution in use. Usually minor defects in packaging or other printed materials.

Reference
EL(26)A/48
Issued
12 Nov 2026
Marketing authorisation holder
Star Pharmaceuticals Ltd

Scan for the official GOV.UK notice, or search GOV.UK for EL(26)A/48.

Pharmshark is not an official alerting route. Make sure your pharmacy receives alerts directly from the MHRA and through your organisation, and always act on the official GOV.UK notice. Printed from pharmshark.com on 21 November 2026; the notice may have changed since, so scan the QR code to check. Source: the MHRA on GOV.UK. Contains public sector information licensed under the Open Government Licence v3.0. Pharmshark is not affiliated with or endorsed by the MHRA.

Pharmacy
Notice received (date)
Date checked
Checked by
Returns / credit reference (if any)

No affected stock found

Batches as listed by the MHRA, exactly as published. Check against the GOV.UK notice before acting.

Enalapril maleate/Hydrochlorothiazide 20 mg/12.5 mg Tablets EL(26)A/48
Batch numberExpiryPack size Packs foundAction takenInitials
Y01819830/06/202728
Y01963531/10/202728
C12548329/02/202828
C13554130/11/202828
Other packs found (write in)
ProductBatch numberExpiry Packs foundAction takenInitials

What needs to be done

  • Note the Class 4 medicines defect notification for the batches listed in the notice.
  • Continue to dispense this product; the notice says the quality of the tablets is not affected by the labelling defect.
  • Pharmacists: if patients ask, reassure them that this is enalapril maleate 20 mg / hydrochlorothiazide 12.5 mg tablets as described in the Patient Information Leaflet (PIL).
  • If a patient reports a suspected adverse reaction, advise that it should be reported via the MHRA Yellow Card scheme.
  • Read and act on the official GOV.UK notice.

Pharmshark summary, checked by Chris Dotchin. It is not the official notice: always read and act on the GOV.UK notice.